29 October 2015

The Company Announcements Platform
ASX Limited
By E-lodgement

Share Purchase Plan fully underwritten up to target amount of $1.03 million

- *Funds to drive next stage development of promising lead drug asset PTX-200*
- *SPP fully underwritten by Patersons Securities up to the target amount of $1.03 million and anticipated to fund key activities and milestones to Q3 2016*
- *Multiple value creation points in next 12 months from PTX-200 trials in breast, ovarian cancers and Acute Myeloid Leukaemia*

Melbourne, Australia, 29 October 2015: Cancer drug development company Prescient Therapeutics Limited (ASX:PTX) (**Company**) is pleased to announce a Share Purchase Plan (**SPP**) fully underwritten up to the target amount of $1.03 million to underpin next stage development of its lead oncology assets.

The SPP provides the opportunity for existing shareholders to subscribe for up to $15,000 in new fully paid ordinary share (**New Shares**) without incurring brokerage or other transaction costs.

The issue price will be determined at the issue date of New Shares under the SPP based on a 20% discount to the volume weighted average price of PTX's shares traded on the ASX during the five (5) days immediately prior to the issue date of the New Shares.

The SPP will be made to Eligible Shareholders, being those who are registered holders of fully paid ordinary shares in the Company as at 7.00pm (Sydney time) on 28 October 2015 (**Record Date**), and whose address in the Company's register is recorded in Australia or New Zealand.

The SPP is fully underwritten by Patersons Securities up to the target amount of $1.03 million. The Company also has discretion to accept applications beyond the underwritten amount. Funds raised will bolster working capital to help provide a 12 month capital runway to further commercial development of lead cancer drug candidate PTX-200. This novel drug works by inhibiting a critical tumour survival pathway known as AKT, which plays a key role in the growth of many cancers.

It is already being examined as a potential new therapy for breast and ovarian cancer patients, with the Company on track to launch a further key study of the drug as a new treatment for patients with Acute Myeloid Leukaemia (AML) next year.

Funds raised will enable the Company to:

- Initiate and complete a Phase 1b Acute Myeloid Leukemia trial at the Moffitt Cancer Center in Florida
- Commence recruitment for a Phase 2 breast cancer trial at the Montefiore Medical Center in New York (part of the Albert Einstein College of Medicine)
- Continue patient recruitment to a key Phase 1b ovarian cancer trial already underway at the Moffitt Cancer Center.

Chairman Steve Engle said the Company is on the brink of realising some of the potential value from its key assets and in particular, from drug candidate PTX-200.

"As noted above, we expect these funds to provide for efforts to achieve multiple milestones across our clinical programs over the next 12 to 18 months," he said.

"Shareholders should note these programs are buoyed by existing strong relationships with highly respected US cancer centers where our trials are being conducted. In addition, our programs are supported by grants from the US Department of Defense and the US National Cancer Institute. In short, we are running these studies frugally with some of the best cancer center partners and experts in the world.

PTX Chief Scientific Officer and co-inventor of PTX-200, Professor Said Sebti, said next stage development was designed to provide further evidence of the drug's value across a range of cancers.

He said all early studies of the compound had delivered promising results, with 17 of 32 AML patients in a Phase 1b trial achieving stable disease after just one treatment cycle.

"Initiating the next AML Phase 1b trial provides great opportunity to build on this earlier data," he said.

"We look forward to generating further evidence that our new drug may help break the cycle of chemotherapy resistance across a range of cancers and improve outcomes for cancer patients."

Timetable

Event	Date
Record Date	28 October 2015 at 7.00pm (Sydney time)
Opening Date	2 November 2015
Closing Date	13 November 2015
Settlement Date	20 November 2015
Issue Date	23 November 2015
Quotation Date	25 November 2015

The timetable is indicative only and subject to change. The Company reserves the right to change the timetable at any time or cancel the SPP at any time before the Issue Date, subject to applicable regulatory requirements.

Full details of the SPP will be set out in a letter to shareholders, together with the SPP Booklet and Application Form for Eligible Shareholders. A copy of the SPP Documents will also be lodged with the ASX.

If you have any enquiries in relation to the SPP, please contact the Company Secretary, Ms Melanie Leydin, on +61 3 9692 7222.

About Prescient Therapeutics (PTX)
PTX is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

Lead drug candidate PTX-200 inhibits an important tumor survival pathway known as AKT, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukaemia. This highly promising compound is now the focus of two current clinical trials. The first is a Phase 1b/2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York. A Phase 1b/2 trial of the compound in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at Florida's Lee Moffitt Cancer Center. These trials are funded in part by grants from the U.S. National Cancer Institute. In addition, PTX is planning a Phase 1b/2 trial evaluating PTX-200 as a new therapy for acute myeloid leukemia.

PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors..

PTX has licensed access to its Co-X-Gene™ platform technology to French biotechnology company Transgene for use in two immunotherapeutic products.

Further Inquiries:

Steven Engle
Chairman
+1 858 922 7768 (US)

Paul Hopper
Executive Director
+61 406 671 515 (Aust)

Rudi Michelson
Monsoon Communications
+61 411 402 737